Back to Search Start Over

An Investigation of Fibulin-2 in Hypertrophic Cardiomyopathy.

Authors :
Ibrahim AM
Roshdy M
Elshorbagy S
Hosny M
Halawa S
Yehia D
Elfawy HA
Eldessouki A
Mohamed F
Ellithy A
Abdelfattah M
Elsawy A
Elkhatib M
Allouba M
Elguindy A
Aguib Y
Yacoub M
Source :
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 29; Vol. 21 (19). Date of Electronic Publication: 2020 Sep 29.
Publication Year :
2020

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart muscle disease, with a prevalence of at least 1 in 500 in the general population. The disease is pleiotropic and is characterized by an increased stiffness of the myocardium, partly due to changes in the extracellular matrix (ECM), with elevated levels of interstitial fibrosis. Myocardial fibrosis is linked to impaired diastolic function and possibly phenotypic heterogeneity of HCM. The ECM consists of a very large number of proteins, which actively interact with each other as well as with myocardial cells. The role of other multiple components of the ECM in HCM has not been defined. Fibulin-2 is a glycoprotein component of the ECM, which plays an important role during embryogenesis of the heart; however, its role in adult myocardium has not been adequately studied. We here describe, for the first time, abnormal expression of fibulin-2 in the myocardium in patients with HCM as compared to normal controls. This abnormal expression was localized in the cytoplasm of myocardial cells and in the interstitial fibroblasts. In addition, fibulin-2 levels, measured by ELISA, were significantly elevated in the serum of patients with HCM as compared to normal controls.

Details

Language :
English
ISSN :
1422-0067
Volume :
21
Issue :
19
Database :
MEDLINE
Journal :
International journal of molecular sciences
Publication Type :
Academic Journal
Accession number :
33003281
Full Text :
https://doi.org/10.3390/ijms21197176